Centocor

A federal class action has been filed against the pharmaceutical company alleging deceptive drug pricing. The lawsuit was filed by the federal government and several state, local government, and employee health plans. It claims Centocor and its parent company Johnson & Johnson have engaged in deceptive drug pricing of Remicade. Johnson & Johnson admitted Remicade has been listed for reimbursement at prices 30% higher than the drug's cost to the physicians who administer it. Physicians can therefore profit from administering the drug, which artificially raises the costs of the drugs to patients and insurance providers.